Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4;4(1):e2035057.
doi: 10.1001/jamanetworkopen.2020.35057.

SARS-CoV-2 Transmission From People Without COVID-19 Symptoms

Affiliations

SARS-CoV-2 Transmission From People Without COVID-19 Symptoms

Michael A Johansson et al. JAMA Netw Open. .

Erratum in

  • Error in Supplement.
    [No authors listed] [No authors listed] JAMA Netw Open. 2021 Feb 1;4(2):e211383. doi: 10.1001/jamanetworkopen.2021.1383. JAMA Netw Open. 2021. PMID: 33576813 Free PMC article. No abstract available.

Abstract

Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.

Objective: To assess the proportion of SARS-CoV-2 transmissions in the community that likely occur from persons without symptoms.

Design, setting, and participants: This decision analytical model assessed the relative amount of transmission from presymptomatic, never symptomatic, and symptomatic individuals across a range of scenarios in which the proportion of transmission from people who never develop symptoms (ie, remain asymptomatic) and the infectious period were varied according to published best estimates. For all estimates, data from a meta-analysis was used to set the incubation period at a median of 5 days. The infectious period duration was maintained at 10 days, and peak infectiousness was varied between 3 and 7 days (-2 and +2 days relative to the median incubation period). The overall proportion of SARS-CoV-2 was varied between 0% and 70% to assess a wide range of possible proportions.

Main outcomes and measures: Level of transmission of SARS-CoV-2 from presymptomatic, never symptomatic, and symptomatic individuals.

Results: The baseline assumptions for the model were that peak infectiousness occurred at the median of symptom onset and that 30% of individuals with infection never develop symptoms and are 75% as infectious as those who do develop symptoms. Combined, these baseline assumptions imply that persons with infection who never develop symptoms may account for approximately 24% of all transmission. In this base case, 59% of all transmission came from asymptomatic transmission, comprising 35% from presymptomatic individuals and 24% from individuals who never develop symptoms. Under a broad range of values for each of these assumptions, at least 50% of new SARS-CoV-2 infections was estimated to have originated from exposure to individuals with infection but without symptoms.

Conclusions and relevance: In this decision analytical model of multiple scenarios of proportions of asymptomatic individuals with COVID-19 and infectious periods, transmission from asymptomatic individuals was estimated to account for more than half of all transmissions. In addition to identification and isolation of persons with symptomatic COVID-19, effective control of spread will require reducing the risk of transmission from people with infection who do not have symptoms. These findings suggest that measures such as wearing masks, hand hygiene, social distancing, and strategic testing of people who are not ill will be foundational to slowing the spread of COVID-19 until safe and effective vaccines are available and widely used.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. The Contribution of Asymptomatic Transmission Under Different Infection Profiles
The top curve in each panel represents the average relative hourly infectiousness, such that while the lower curves change under different assumptions, the total hourly infectiousness equals 1 in all cases. Within each curve, the colored area indicates the proportion of transmission from each class of individuals. The portion attributed to individuals with symptoms (light blue) can also be interpreted as the maximum proportion of transmission that can be controlled by immediate isolation of all symptomatic cases. Panels A, B, and C show different levels of presymptomatic transmission. We calibrated infectiousness to peak at day 4 (A), 5 (B; median incubation period), or 6 (C) days. Panels D, E, and F show different proportions of transmission from individuals who are never symptomatic: 8% (C; eg, 10% never symptomatic and 75% relative infectivity), 24% (D; baseline, 30% never symptomatic and 75% relative infectivity), and 30% (E; eg, 30% never symptomatic and 100% relative infectivity).
Figure 2.
Figure 2.. Combined Transmission From Individuals Who Are Presymptomatic and Those Who Never Have Symptoms
Colors indicate the proportion of transmission due to all individuals without symptoms at the time of transmission, including presymptomatic transmission (x-axis, the timing of peak infectiousness relative to symptom onset) and transmission from individuals who are never symptomatic (y-axis). For example, peak infectiousness at the same time as median symptom onset (0 days difference) with 10% of transmission from individuals who never have symptoms would mean that approximately 51% of transmission is from asymptomatic individuals.

Similar articles

Cited by

References

    1. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349(25):2431-2441. doi:10.1056/NEJMra032498 - DOI - PubMed
    1. Tindale LC, Stockdale JE, Coombe M, et al. . Evidence for transmission of COVID-19 prior to symptom onset. Elife. 2020;9:e57149. doi:10.7554/eLife.57149 - DOI - PMC - PubMed
    1. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis. 2020;93:284-286. doi:10.1016/j.ijid.2020.02.060 - DOI - PMC - PubMed
    1. Zhao S, Gao D, Zhuang Z, et al. . Estimating the serial interval of the novel coronavirus disease (COVID-19): a statistical analysis using the public data in Hong Kong from January 16 to February 15, 2020. Front Phys. Published online September 17, 2020. doi:10.3389/fphy.2020.00347 - DOI
    1. Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis. 2020;26(6):1341-1343. doi:10.3201/eid2606.200357 - DOI - PMC - PubMed

Publication types